Hepatitis C virus therapy in liver transplant recipients: response predictors, effect on fibrosis progression, and importance of the initial stage of fibrosis.

摘要: Antiviral therapy after liver transplantation (LT) using interferon (IFN) and ribavirin (RBV) can achieve a sustained virological response (SVR) rate ranging from 20% to 45%. The aims of our study were assess efficacy tolerability therapy, effect on fibrosis progression the importance initial stage outcome. A total 113 hepatitis C virus (HCV)-infected LT patients received 133 courses IFN (standard, n = 29, pegylated [pegIFN], 104) RBV (75% genotype 1). Early (EVR), end-of-treatment (EOT), SVR obtained in 74%, 55%, 38%, respectively. EVR, completion treatment, viral load before non-1, use pegIFN predictive SVR, but only EVR remained multivariate analysis. was 45% who second course therapy. Paired biopsies at baseline, EOT long-term available 42 patients. mean stable with increased without response. Rejection episodes observed 6% Tolerability decrease ≥3 baseline biopsy. them died or retransplanted due failure as opposed 1% had <3. In conclusion, achieved 38% is independently associated SVR. Fibrosis nonresponders. high failure, arguing for an early introduction antiviral Liver Transpl 14:1766–1777, 2008. © 2008 AASLD.